Study to Assess the Efficacy of Intralesional Corticosteroid on the Treatment of Frontal Fibrosing Alopecia

NCT ID: NCT02467101

Last Updated: 2015-06-09

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-07-31
• Study Completion Date: 2015-12-31

Brief Summary

The purpose of this study is to determine the efficacy of treatment with intralesional injection of corticosteroids on the treatment of Frontal Fibrosing Alopecia (compared with placebo), between three months, six months and baseline.

Detailed Description

Frontal fibrosing alopecia (FFA) is a primary lymphocytic cicatricial alopecia, that was first described in postmenopausal women, by Kossard in 1994. Since then, FFA has also been reported in premenopausal women and rarely in men.

The exact cause of FFA is unknown. One possible reason can be the disturbed immune response to some component of the scalp hair follicles, however, whether or not the hair loss is caused by hormonal fluctuations is under question. Some authors, consider that FFA is a variant of liquen planopilaris (LPP). Whether FFA is truly an LPP variant or is a distinct entity with shared clinical features remains to be determined. FFA was also diagnosed in family members (mother and daughter) suggesting a possible genetic contribution.

Clinically, it is characterized by progressive frontal and temporoparietal recession of the hairline due to inflammatory destruction of hair follicles. Hair loss occurs in a band-like distribution and the depth of recession can be from 0,5-8 cm. Often, a small number of isolated hairs are spared within the band of alopecia.

Loss of eyebrows (partial or complete) is a finding in FFA and in some cases, can precede the hairline recession. The affected skin is atrophic, shiny, and often lighter than the chronically sun-exposed forehead skin.

The diagnosis of FFA is usually made on the basis of clinical findings, and laboratory tests are rarely required. Dermoscopy, a noninvasive tool can help for the diagnosis of FFA; The dermoscopic features of FFA are: Absence of follicular openings, perifollicular scale, and a feeble perifollicular erythema. Perifollicular erythema at the receding hairline may be a sign of active disease.

Since the first description of FFA, many reports have been published, and the number of new cases of FFA appears to be increasing.

Currently, there are no evidence-based studies to guide treatment and there is no clearly defined line of treatment for the condition. Therefore treatment options vary among clinicians.

The aim of this study is to find if intralesional triamcinolone acetonide (compared to area treated with placebo) may help to halt or slow down the progression of this disease.

The patients are divided into two groups (A and B):

1. Group A: right half-head (active border of the disease): treatment with intralesional triamcinolone acetonide left half-head (active border of the disease): placebo (saline solution)

2. Group B: right half-head (active border of the disease):placebo (saline solution)

left half-head (active border of the disease): intralesional triamcinolone acetonide

The aim of this study is to find if intralesional triamcinolone may help to halt or slow down the progres- sion of this disease.

All patients provide written informed consent before participating in the study, which is performed according to the Declaration of Helsinki.

Conditions

Frontal Fibrosing Alopecia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Corticosteroid/Saline

Corticosteroid/Saline

Patients with diagnosis of frontal fibrosing alopecia are included in the study. The diagnosis is based on the clinical findings of frontal and temporoparietal hairline recession with loss of follicular ostia.

In the same patient, intralesional triamcinolone acetone will be injected to half-head (in the active border of hairline) and in the other half-head the patient will be injected with saline solution (placebo).

The intralesional triamcinolone acetone (40 mg/ml)l) of 0,1 mL/1cm, is given along the frontal and frontoparietal hairline every 4 weeks (3 sessions).

This study includes 4 visits: 3 visits of treatment (with 1-month interval) and 1 visit of follow-up (month 6).

Group Type: EXPERIMENTAL

Corticosteroid/Saline

Intervention Type: OTHER

Corticosteroid/Saline

Two groups were defined: group A and group B.

• Group A receives treatment with intralesional triamcinolone acetonide on the right half-head and placebo on the left half-head
• Group B receives administration of intralesional triamcinolone acetonide on left half-head and placebo on the right half-head.

Same patient will be injected with intralesional triamcinolone acetonide and a saline solution.

Each patient will be injected on half-head.

Interventions

Corticosteroid/Saline

Corticosteroid/Saline

Two groups were defined: group A and group B.

• Group A receives treatment with intralesional triamcinolone acetonide on the right half-head and placebo on the left half-head
• Group B receives administration of intralesional triamcinolone acetonide on left half-head and placebo on the right half-head.

Same patient will be injected with intralesional triamcinolone acetonide and a saline solution.

Each patient will be injected on half-head.

Intervention Type: OTHER

Other Intervention Names

Frontal fibrosing alopecia; Cicatricial alopecia; Alopecia; Hair loss

Eligibility Criteria

Inclusion Criteria

• Patients with the diagnosis of Frontal Fibrosing Alopecia

Exclusion Criteria

• Pregnancy
• Patient unable to accomplishing all fases of treatment

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Universitat Internacional de Catalunya

OTHER

Sponsor Role: collaborator

Rubina Alves

OTHER

Sponsor Role: lead

Responsible Party

Rubina Alves

Specialist Dermatology, M.D.

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Rubina Alves, M.D.

Role: PRINCIPAL_INVESTIGATOR

Universitat Internacional Catalunya

Juan Antonio Moreno, M.D.

Role: PRINCIPAL_INVESTIGATOR

Universitat Internacional Catalunya

Ramon Grimalt, M.D.; PhD

Role: STUDY_DIRECTOR

Universitat Internacional Catalunya

Locations

Universitat Internacional Catalunya

Barcelona, Barcelona, Spain

Countries

Spain

Central Contacts

Rubina Alves, M.D..

Role: CONTACT

rubinaalves@gmail.com

00351913814831

Other Identifiers

UICatalunya

Identifier Type: REGISTRY

Identifier Source: secondary_id

UIC-FFA

Identifier Type: -

Identifier Source: org_study_id